Nobiletin, a polymethoxyflavone in citrus fruits, reduces TAFI expression in HepG2 cells through transcriptional inhibition

Summary

Thrombin-activatable fibrinolysis inhibitor (TAFI, carboxypeptidase B2) is a 58-kDa plasma glycoprotein secreted by hepatocytes as an inactive form. TAFI is activated by the thrombin-thrombomodulin complex, and activated TAFI (TAFIa) plays an important role in regulating the balance between coagulation and fibrinolysis through inhibition of fibrinolysis. It has been suggested that high levels of TAFI in circulating plasma increase the risks of cardiovascular death and acute phase in ischaemic stroke. However, the mechanisms of regulating TAFI expression have been unclear. The present study investigated the effects of nobiletin (a polymethoxy flavonoid contained in the rind of citrus fruits) on TAFI gene (CPB2) and TAFI antigen expression in cultured human hepatoma HepG2 cells. Nobiletin decreased the release of TAFI antigen from HepG2 cells into conditioned medium in parallel with decreased levels of CPB2 mRNA and antigen. The half-life time of CPB2 mRNA in nobiletin-treated cells was unchanged compared to that of untreated control cells. Using nobiletin-treated cells that were transfected with a luciferase CPB2 promoter reporter plasmid, activity decreased to half of that in untreated control cells. A series of luciferase reporter constructs containing 5´-flanking region deletions of the human CPB2 gene showed that the sequences from –150 bp to –50 bp were essential for transcription of CPB2 and contained an AP-1 binding sequence at ∼ –119 bp to – 99 bp in the CPB2 promoter. The amount of complexed nuclear protein and sequences from ∼ –119 bp to –99 bp was decreased in nobiletin-treated cells. ChIP assays showed that c-Jun bound to the ∼ –119 bp to –99 bp region of the CPB2 promoter and that the amount of the immunocomplex decreased after nobiletin treatment. Therefore, nobiletin-induced repression of CPB2 transcription might involve AP-1 inhibition and/or prevention of AP-1 binding in a specific region on the CPB2 gene in HepG2 cells.

Keywords

Thrombin-activatable fibrinolysis inhibitor (TAFI) - fibrinolysis - AP-1 - CPB2 - HepG2 cells - nobiletin

• References

• 1 Bouma BN, Marx PF, Mosnier LO. et al. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101: 329-354.
• 2 Montaner J, Ribo M, Monasterio J. et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischaemic stroke. Stroke 2003; 34: 1038-1040.
• 3 Leebeek FW, Goor MP, Guimaraes AH. et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischaemic stroke. J Thromb Haemost 2005; 03: 2211-2218.
• 4 Rooth E, Wallen H, Antovic A. et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischaemic stroke. Blood Coagul Fibrinolysis 2007; 18: 365-370.
• 5 Yano Y, Kitagawa N, Gabazza EC. et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88: 736-741.
• 6 de Bruijne ELE, Gils A, Rijken DC. et al. High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res 2011; 127: 254-258.
• 7 Morange PE, Tregouet DA, Frere C. et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 2005; 03: 1503-1510.
• 8 Verdu J, Marco P, Benlloch S. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost 2006; 95: 585-586.
• 9 Biswas A, Tiwari AK, Ranjan R. et al. Thrombin activatable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian-Indian population but may not be a risk for stroke. Br J Haematol 2008; 143: 581-588.
• 10 Boffa MB, Hamill JD, Bastajian N. et al. A role for CCAAT/enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor. J Biol Chem 2002; 277: 25329-25336.
• 11 Boffa MB, Hamill JD, Maret D. et al. Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells. J Biol Chem 2003; 278: 9250-9257.
• 12 Garand M, Bastajian N, Nesheim ME. et al. Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter. Br J Haematol 2007; 138: 231-244.
• 13 Lin N, Sato T, Takayama Y. et al. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol 2003; 65: 2065-2071.
• 14 Kawabata K, Murakami A, Ohigashi H. Nobiletin, a citrus flavonoid, downregulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. Biosci Biotechnol Biochem 2005; 69: 307-314.
• 15 Sato T, Koike L, Miyata Y. et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and −9 in human fibrosarcoma HT-1080 cells. Cancer Res 2002; 62: 1025-1029.
• 16 Hirata Y, Masuda Y, Kakutani H. et al. Sp1 is an essential transcription factor for LPS-induced tissue factor expression in THP-1 monocytic cells, and nobiletin represses the expression through inhibition of NF-kappaB, AP-1, and Sp1 activation. Biochem Pharmacol 2008; 75: 1504-1514.
• 17 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
• 18 Eaton D, Malloy B, Tsai S. et al. Isolation, molecular cloning, and partial characterisation of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
• 19 Gussow D, Rein R, Ginjaar I. et al. The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 1987; 139: 3132-3138.
• 20 Wilson GM, Deeley RG. An episomal expression vector system for monitoring sequence-specific effects on mRNA stability in human cell lines. Plasmid 1995; 33: 198-207.
• 21 Schreiber E, Matthias P, Muller MM. et al. Rapid detection of octamer binding proteins with ‘mini-extracts’, prepared from a small number of cells. Nucleic Acids Res 1989; 17: 6419.
• 22 Ishii H, Takada K, Higuchi T. et al. Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-1. Thromb Haemost 2000; 84: 712-721.
• 23 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
• 24 Ishii H, Kojima Y, Masuda Y. et al. Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) is up-regulated by increase in intracellular cyclic AMP levels in cultured HepG2 cells. Thromb Haemost 2009; 102: 1204-1211.
• 25 Willemse JL, Hendriks DF. Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge. Clin Chem 2006; 52: 30-36.
• 26 Heylen E, Miljic P, Willemse J. et al. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res 2009; 124: 427-432.
• 27 Tregouet DA, Schnabel R, Alessi MC. et al. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Thromb Haemost 2009; 07: 49-57.
• 28 Miyata Y, Sato T, Imada K. et al. A citrus polymethoxyflavonoid, nobiletin, is a novel MEK inhibitor that exhibits antitumor metastasis in human fibrosarcoma HT-1080 cells. Biochem Biophys Res Commun 2008; 366: 168-173.